After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.
News: CureVac COVID vaccine let-down spotlights mRNA design challenges
News Feature: How COVID unlocked the power of RNA vaccines
Never miss an episode: Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favourite podcast app. Head here for the Nature Podcast RSS feed.
Step aside CRISPR, RNA editing is taking off
WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic
Pfizer COVID vaccine protects against worrying coronavirus variants
